Trials / Completed
CompletedNCT02136563
Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents
oBservational Clinical Research In Chronic Kidney Disease Patients With Renal Anemia : Renal proGnosis in Patients With Hyporesponsive Anemia To Erythropoiesis Stimulating Agents, darbepoetiN Alfa
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational clinical research on patients with chronic kidney disease who are not on hemodialysis and receiving darbepoetin alfa to treat diagnosed renal anemia; the major objective is to explore novel erythropoiesis stimulating agent (ESA) response index in association with deterioration of renal function as well as occurrence of cardiovascular disease events.
Conditions
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2014-05-13
- Last updated
- 2020-06-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02136563. Inclusion in this directory is not an endorsement.